Drug intelligence / Profile preview

MSD-001

Development stage: Phase 1
Lead developer: Mindstate Design Labs
Modality: Small Molecules
Administration: Oral

Overview

MSD-001 is an orally administered formulation of 5-MeO-MiPT (commonly called "moxy"), being developed by Mindstate Design Labs for the treatment of mental disorders. It is described as a "psychedelic tofu" due to its mild effects at clinical doses and high specificity for serotonin receptors. MSD-001 acts as a serotonin receptor modulator and is designed to temporarily enable significant emotional and cognitive flexibility. The compound is intended to serve as a base substance that can be combined with other drugs to target precise serotonin receptors in the brain and create customized states of consciousness with therapeutic potential.

Brand names: Moxy
Other names: 5-MeO-MiPT

Targets

5-HT (Serotonin receptors)

Beyond the preview

Go deeper on MSD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSD-001.

Explore the full profile